January 12, 2020 / 10:49 PM / 14 days ago

BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog

Jan 12 (Reuters) - Iovance Biotherapeutics Inc:

* IOVANCE BIOTHERAPEUTICS OBTAINS LICENSE TO DEVELOP AND COMMERCIALIZE A NOVEL IL-2 ANALOG

* OBTAINED A LICENSE FROM NOVARTIS TO DEVELOP AND COMMERCIALIZE AN ANTIBODY CYTOKINE ENGRAFTED PROTEIN, REFERRED TO AS IOV-3001

* NOVARTIS IS ALSO ENTITLED TO LOW-TO-MID SINGLE DIGIT ROYALTIES FROM COMMERCIAL SALES OF PRODUCT

* UNDER AGREEMENT, CO WILL PAY AN UPFRONT PAYMENT TO NOVARTIS AS WELL AS LOW SINGLE DIGIT MILESTONES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below